[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Castle Biosciences Inc (CSTL)

Castle Biosciences Inc (CSTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 601,444
  • Shares Outstanding, K 30,330
  • Annual Sales, $ 344,230 K
  • Annual Income, $ -24,160 K
  • EBIT $ -8 M
  • EBITDA $ 29 M
  • 60-Month Beta 1.11
  • Price/Sales 1.70
  • Price/Cash Flow 17.28
  • Price/Book 1.26

Options Overview Details

View History
  • Implied Volatility 78.88% (+3.08%)
  • Historical Volatility 83.80%
  • IV Percentile 81%
  • IV Rank 60.68%
  • IV High 101.74% on 02/20/26
  • IV Low 43.60% on 08/19/25
  • Expected Move (DTE 5) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 2
  • Volume Avg (30-Day) 99
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 664
  • Open Int (30-Day) 763
  • Expected Range 19.83 to 19.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.38
  • Number of Estimates 1
  • High Estimate $-0.38
  • Low Estimate $-0.38
  • Prior Year $0.15
  • Growth Rate Est. (year over year) -353.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.31 +8.30%
on 05/07/26
25.72 -22.89%
on 04/21/26
-5.36 (-21.28%)
since 04/08/26
3-Month
18.31 +8.30%
on 05/07/26
34.44 -42.42%
on 02/18/26
-12.92 (-39.45%)
since 02/06/26
52-Week
14.59 +35.92%
on 08/04/25
44.28 -55.22%
on 01/26/26
+2.62 (+15.22%)
since 05/08/25

Most Recent Stories

More News
Castle Biosciences Reports First Quarter 2026 Results

Delivered Q1 2026 revenue of $83.7 million Q1 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased...

CSTL : 19.83 (+3.07%)
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month

Longstanding   collaborations with   AIM at Melanoma, the Melanoma Research Foundation,   The   Skin Cancer Foundation, IMPACT Melanoma and The   Sun Bus continue to   advance...

CSTL : 19.83 (+3.07%)
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus

Clinical studies from Mayo Clinic researchers demonstrate the TissueCypher test provides improved risk stratification and influences risk-aligned surveillance decisions in clinical practice, with one study...

CSTL : 19.83 (+3.07%)
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS

Multi-center clinical and population-based data show that DecisionDx-Melanoma identifies biologically high-risk patients—including those with thin and early-stage disease—and provides recurrence risk...

CSTL : 19.83 (+3.07%)
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026

FRIENDSWOOD, Texas , April 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will...

CSTL : 19.83 (+3.07%)
Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year

FRIENDSWOOD, Texas , April 10, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has...

CSTL : 19.83 (+3.07%)
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026

Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee...

CSTL : 19.83 (+3.07%)
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) by...

CSTL : 19.83 (+3.07%)
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Study results were recently shared at the  Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy...

CSTL : 19.83 (+3.07%)
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data...

CSTL : 19.83 (+3.07%)

Business Summary

Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.

See More

Key Turning Points

3rd Resistance Point 21.42
2nd Resistance Point 20.64
1st Resistance Point 20.23
Last Price 19.83
1st Support Level 19.04
2nd Support Level 18.26
3rd Support Level 17.85

See More

52-Week High 44.28
Fibonacci 61.8% 32.94
Fibonacci 50% 29.43
Fibonacci 38.2% 25.93
Last Price 19.83
52-Week Low 14.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.